HIKAL
|
The Current P/E Ratio of HIKAL is -74.45.
| Share Price | ₹204.1 | Aug 28,2026 |
| Market Cap | ₹2,516.6 Cr | |
| Earnings-TTM | ₹-33.8 Cr | TTM-Consolidated Results |
| Price/Earnings | -74.45x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of HIKAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,516.6 Cr] as on Aug 28,2026
(/) Earnings [ ₹-33.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -74.45x ]
Thus, for HIKAL , the investors are currently willing to pay -74.45 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of HIKAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of HIKAL over the last five years.
Historical PE (Price/Earnings) ratio chart of HIKAL
PE Ratio Performance Analysis for HIKAL
- HIKAL 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 37.99x.
- HIKAL 's operated at median p/e ratio of 44.34x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, HIKAL 's p/e ratio peaked in Mar2025 at 54.42x.
- HIKAL 's p/e ratio hit its five-year low in Mar2021 of 13.29x.
How does HIKAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| HIKAL | -33.80 | -74.45 | 2,516.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.85 | 460,696.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 84.12 | 246,063.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 88.83 | 191,515.0 |
| CIPLA LTD | 3,364.84 | 34.04 | 114,554.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.02 | 98,308.6 |
| MANKIND PHARMA LTD | 2,055.11 | 47.98 | 98,598.7 |
| LUPIN LTD | 5,551.01 | 17.92 | 99,455.3 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 26.36 | 118,404.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.57 | 94,937.4 |
| LAURUS LABS LTD | 1,090.76 | 95.87 | 104,567.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs HIKAL 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -74.45x |
| Max industry PE | 95.87x |
| Median industry PE | 34.04x |
| Average industry PE | 37.74x |
You may also like the below Video Courses